Leading the Way in Life Science Technologies

GEN Exclusives

More »

Press Releases

More »
Aug 5, 2013

Leonard Schleifer Heads GEN’s List of Top Money-Making Biopharma CEOs

  • New Rochelle, NY, August 5, 2013—Leonard Schleifer, M.D., Ph.D., president and CEO of Regeneron Pharmaceuticals (NASDAQ: REGN), moved into the top spot on the GEN list of the highest-paid biopharma CEOs with a total compensation package of $30,047,097 in 2012. William Weldon, former chairman/CEO of Johnson & Johnson (NYSE:JNJ), came in second place after tallying $29,838,259 a year ago, according to GEN.

    “Dr. Schleifer’s biopharma-related financial status actually grew by an astounding 184.5% from 2011,” says John Sterling, editor in chief of GEN. “This was largely due, no doubt, to the FDA’s approval last year of Regeneron’s Eylea, a drug for the treatment of wet age-related macular degeneration. The product has also been approved for use in Europe and Japan.”

    The number 3, 4, and 5 positions on the GEN list were filled, respectively, by Ian Read, chairman and CEO of Pfizer (NYSE:PFE), $25,634,136; Lamberto Andreotti, CEO of Bristol-Myers Squibb (NYSE:BMY), $17,201,980; and Ken Frazier, chairman, president, and CEO of Merck & Co. (NYSE:MRK), $15,459,607.

    This year’s list saw two key changes. One is that this year’s rankings are of individuals rather than companies, since two of last year’s Top 10 companies had more than one CEO during 2012. And the list has expanded to a Top 15, to ensure inclusion of all four CEOs with compensation in the $13.5 million range, rather than just one, and to better illustrate the spread beyond U.S. big pharma of compensation packages at or close to the eight-figure range.

    To see the entire listing of GEN’s Top 15 Money-Making Biopharma CEOs, please click here.


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »